Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group has announced that its Dupilumab Injection, a biosimilar targeting IL-4Rα for treating moderate-to-severe atopic dermatitis in adults, has received approval from China’s National Medical Products Administration for clinical trials. This approval marks a significant step in the company’s efforts to expand its biosimilar portfolio and strengthen its position in the Chinese pharmaceutical market, potentially impacting stakeholders positively by enhancing treatment options and driving growth.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on developing and manufacturing a range of pharmaceutical products, including biosimilars, with a market focus on China.
Average Trading Volume: 219,361,698
Technical Sentiment Signal: Buy
Current Market Cap: HK$126.1B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.